ATYR
aTyr Pharma, Inc.NASDAQHealthcare$0.85-0.46%ClosedMarket Cap: $83.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.20
P/S
425.23
EV/EBITDA
-1.09
DCF Value
$-0.04
FCF Yield
-76.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
-11754.7%
Operating Margin
-40856.3%
Net Margin
-39009.5%
ROE
-99.6%
ROA
-78.7%
ROIC
-96.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-14.8M | $-14.0M | $-0.14 | — |
| FY 2025 | $190.0K | -717.4% | $-77.6M | $-74.1M | $-0.80 | — |
| Q3 2025 | $190.0K | -11547.4% | $-26.7M | $-25.7M | $-0.26 | — |
| Q2 2025 | $0.00 | NaN% | $-20.3M | $-19.5M | $-0.22 | — |
| Q1 2025 | $0.00 | NaN% | $-15.8M | $-14.9M | $-0.17 | — |
| Q4 2024 | $0.00 | -Infinity% | $-15.8M | $-15.0M | $-0.18 | — |
| FY 2024 | $235.0K | 100.0% | $-67.9M | $-64.0M | $-0.86 | — |
| Q3 2024 | $0.00 | NaN% | $-18.1M | $-17.3M | $-0.23 | — |
| Q2 2024 | $0.00 | NaN% | $-17.3M | $-16.3M | $-0.23 | — |
| Q1 2024 | $235.0K | 100.0% | $-16.6M | $-15.5M | $-0.23 | — |
| Q4 2023 | $0.00 | -Infinity% | $-16.0M | $-14.8M | $-0.25 | — |
| FY 2023 | $353.0K | 100.0% | $-54.9M | $-50.4M | $-0.94 | — |